Scope Fluidics

Scope Fluidics Working Capital

The Working Capital of Scope Fluidics (SCP.WA) as of Oct 30, 2026 is 150.63 M PLN. In the previous year, Working Capital was 137.58 M PLN — a change of 9.49% (higher).

Working Capital

150.63 MPLN

YoY

9.49%

Last updated:

Working Capital of Scope Fluidics is 2025 150.63 M PLN. Working Capital of Scope Fluidics was 2024 137.58 M PLN. It decreases by 9.49% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Working Capital of Scope Fluidics is 150.63 M PLN in 2025.

Working Capital of Scope Fluidics changed from 137.58 M PLN to 150.63 M PLN, representing a 9.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Scope Fluidics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scope Fluidics

All Key Metrics — Scope Fluidics